Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 501–600 of 895
Discrete mixture modeling to address genetic heterogeneity in time-to-event regression
Eng, K. H., & Hanlon, B. M. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu065 · Cited by 15
Clinical implications of using molecular diagnostics for ovarian cancers
Kohn, E. C., Romano, S., & Lee, J.-M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt464 · Cited by 15
“There are no data to date in non-BRCA1/2 mut+ EOCs of nonhighgrade serous histology to help answer this directly.”
InfluentialSupervised clustering of high-dimensional data using regularized mixture modeling
Chang, W., Wan, C., Zang, Y., Zhang, C., & Cao, S. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa291 · Cited by 15
“This implies that the same predicative model that links molecular markers to a phenotypic trait may not be valid for every patient, and further it is unclear to what extent the patients should be considered together [5].”
BackgroundRodriguez, M., Kang, E. Y., Farrington, K., Cook, L. S., Le, N. D., Karnezis, A. N., Lee, C., Nelson, G. S., Terzić, T., Lee, S., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001798 · Cited by 15
Self-citationRobotti, M., Scebba, F., & Angeloni, D. (2023) · Biomedicines · doi:10.3390/biomedicines11030652 · Cited by 15
Skírnisdóttir, I., Seidal, T., & Åkerud, H. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000484 · Cited by 15
“dichotomized into negative and positive (+, ++, +++) cases.(23) However, for PUMA, weak positive staining (+) was graded as negative (j), and moderate/strong staining (++/+++) graded as positive.”
BackgroundSullivan, M. W., Camacho, F., Mills, A. M., & Modesitt, S. C. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.029 · Cited by 15
Mohan, R. (2012) · InTech eBooks · doi:10.5772/1781 · Cited by 15
Autoantibodies to Mesothelin in Infertility
Luborsky, J. L., Yu, Y., Edassery, S. L., Jaffar, J., Yip, Y. Y., Liu, P., Hellstrom, K.-E., & Hellström, I. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0139 · Cited by 15
“This is also consistent with differences in expression profiles among different tumor subtypes (67, 68).”
ResultNobel, S. M. N., Swapno, S. M. M. R., Hossain, M. A., Safran, M., Alfarhood, S., Kabir, M. M., & Mridha, M. F. (2024) · Tomography · doi:10.3390/tomography10010010 · Cited by 14
RetractedAntibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules
Katoh, M., Loriot, Y., Nakayama, I., Hamada, A., Shitara, K., & Katoh, M. (2025) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2025.1661016 · Cited by 14
Virani, S., Baiocchi, G., Bowtell, D. D. L., Cabasag, C. J., Cho, K. R., Fortner, R. T., Fujiwara, K., Kim, J., Köbel, M., Kurtz, J., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab043 · Cited by 14
“Recently, ovarian carcinoma research has evolved considerably because of the emerging recognition that rather than a single disease but comprises several different histotypes that vary by etiologic origin, risk factors, molecular profiles, therapeutic approaches and clinical outcome (2).”
BackgroundSelf-citationHaslene‐Hox, H., Madani, A., Berg, K. C. G., Woie, K., Salvesen, H. B., Wiig, H., & Tenstad, O. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.08.002 · Cited by 14
Kelemen, L. E., Abbott, S., Qin, B., Peres, L. C., Moorman, P. G., Wallace, K., Bandera, E. V., Barnholtz‐Sloan, J. S., Bondy, M. L., Cartmell, K. B., et al. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0899-6 · Cited by 14
Kanai, T., Ito, Z., Oji, Y., Suka, M., Nishida, S., Takakura, K., Kajihara, M., Saruta, M., Fujioka, S., Misawa, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8961 · Cited by 14
“…previous studies have demonstrated that WT1 serves an important role in the prognosis of patients with tumors, including ovarian cancer (16,17), hepatocellular carcinoma (18), breast cancer (19) and acute leukemia (20), and WT1 protein overexpression is associated with a poor prognosis…”
Wilms’ tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis
Lu, J., Gu, Y., Li, Q., Zhong, H., Wang, X., Zheng, Z., Hu, W., & Wen, L. (2018) · Medicine · doi:10.1097/md.0000000000011485 · Cited by 14
“DSS Multi Köbel et al[17] CA OC 1984–2000 Median 61 174/493 (35”
BackgroundInfluentialSkírnisdóttir, I., Åkerud, H., & Seidal, T. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4511 · Cited by 14
“A semi-quantitative analysis (14) was performed and the staining was graded as negative, +, ++, and +++ for EGFR and VEGF-R2, and both of the markers were dichotomized into negative and positive (+,++ and +++) cases (15).”
Analysis of PAX8 immunohistochemistry in lung cancers: a meta-analysis
Jeong, J. H., Kim, N. Y., & Pyo, J. (2020) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2020.06.08 · Cited by 14
“PAX8 can be expressed in the neoplastic cells of associated organs and is expressed both in the normal tissues and tumors from these organs [25-29].”
BackgroundEmerging roles of lamins and DNA damage repair mechanisms in ovarian cancer
Sengupta, D., Mukhopadhyay, A., & Sengupta, K. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200713 · Cited by 14
Huvila, J. K., Cochrane, D. R., Ta, M., Chow, C., Greening, K., Leung, S. C. Y., Karnezis, A. N., DiFeo, A. V., & Huntsman, D. D. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.230 · Cited by 14
“One of the two cohorts in this study has been previously described [23].”
Self-citationParadigm Shift in the Management Strategy for Epithelial Ovarian Cancer
Fujiwara, K., McAlpine, J. N., Lheureux, S., Matsumura, N., & Oza, A. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158675 · Cited by 14
Wang, C., Wen, A., Qiao, J., Liu, Y., Guo, Y., & Wang, W. (2020) · Medical Science Monitor · doi:10.12659/msm.921370 · Cited by 14
Nafisi, H., Cesari, M., Karamchandani, J., Balasubramaniam, G., & Keith, J. L. (2014) · Neuropathology · doi:10.1111/neup.12172 · Cited by 14
Radiation Therapy for Recurrent Clear-Cell Cancer of the Ovary
Westhoff, G. L., Fuh, K. C., Longacre, T., McNally, L. J., Hsu, I.-C. J., Kapp, D. S., Teng, N. N. H., & Chen, L.-M. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000810 · Cited by 14
Ligr, M., Patwa, R. R., Daniels, G., Pan, L. Y., Wu, X., Li, Y., Tian, L., Wang, Z., Xu, R., Wu, J., et al. (2011) · PLoS ONE · doi:10.1371/annotation/fe4fca93-8211-430e-bfe0-8a371b9cc20d · Cited by 14
Novel antibody-drug conjugates based on DXd-ADC technology
Chen, R., Ren, Z., Bai, L., Hu, X., Chen, Y., Ye, Q., Hu, Y. J., & Shi, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107697 · Cited by 14
Takamatsu, S., Hillman, R. T., Yoshihara, K., Baba, T., Shimada, M., Yoshida, H., Kajiyama, H., Oda, K., Mandai, M., Okamoto, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02837-x · Cited by 14
Amsterdam, A., Shezen, E., Raanan, C., Schreiber, L., Prus, D., Slilat, Y., Ben‐Arie, A., & Seger, R. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1090 · Cited by 13
Wiiger, M. T., Bideli, H., Fodstad, Ø., Flatmark, K., & Andersson, Y. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-23 · Cited by 13
“In a retrospective study of 500 ovarian cancer patients, EpCAM showed consistently high expression across different tumor stages and subtypes [5] and the protein was over-expressed in cancerous tissues compared with non-cancerous ovarian surface epithelium and inclusion cysts [6].”
Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix
Wong, S. T.-L., Hong, W., Hui, P., & Buza, N. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000309 · Cited by 13
Sub-terahertz vibrational spectroscopy for microRNA based diagnostic of ovarian cancer
Globus, T. R., Sizov, I., Ferrance, J. P., Jazaeri, A. A., Bryant, J., Moyer, A., GELMONT, B. L., KESTER, M. A., & Bykhovski, A. (2016) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/2/4/045001 · Cited by 13
“Each of these histotypes has been found to be associated with mutations in specific genes and have different clinical manifestations (Köbel et al 2008).”
BackgroundAugmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors
Choi, H., Ignacio, R. M. C., Lee, E.-S., Wilson, A. J., Khabele, D., & Son, D. (2017) · Immune Network · doi:10.4110/in.2017.17.2.121 · Cited by 13
“2: 121-127, April, 2017 122 lethal subtype of ovarian cancer (3).”
BackgroundLiu, W., Tian, X., Ding, X., & Zhang, L. (2019) · Medical Science Monitor · doi:10.12659/msm.919089 · Cited by 13
“Worldwide, ovarian carcinoma is one of the most prevalent gynecologic malignancies and includes four major histological subtypes, clear cell carcinoma, endometrioid carcinoma, mucinous adenocarcinomas, and serous carcinoma [1].”
BackgroundXiao, Y., Lai, Y., Yu, Y., Jiang, P., Li, Y., Wang, C., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669603 · Cited by 13
Andersson, C., Oji, Y., Ohlson, N., Wang, S., Li, X., Ottander, U., Lundin, E., Sugiyama, H., & Li, A. (2014) · Cancer Medicine · doi:10.1002/cam4.244 · Cited by 13
“showed that WT1 is a favorable prognostic marker in the high-grade serous OC [26].”
BackgroundResultMadsen, C. V., Steffensen, K. D., Waldstrøm, M., & Jakobsen, A. K. M. (2012) · Pathology Research International · doi:10.1155/2012/851432 · Cited by 13
Chang, Y., Greinix, H., Dickinson, A. M., Wolff, D., Jackson, G. H., Andreesen, R., Holler, E., & Hildebrandt, G. C. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.012 · Cited by 13
Patterns of spread of clear cell ovarian cancer: Case report and case series
Kumar, A., Gilks, C. B., Mar, C., Santos, J. L., & Tinker, A. V. (2013) · Gynecologic Oncology Case Reports · doi:10.1016/j.gynor.2013.07.008 · Cited by 13
“Ovarian carcinomas are represented by a number ofmolecularly distinct diseases broadly defined by histotype, with different outcomes, patterns of relapse and response to therapy (Kobel et al., 2008).”
Self-citationLi, Y., & Zhang, J. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000275 · Cited by 13
Zapardiel, I., Gorostidi, M., Ravaggi, A., Allende, M. T., Silveira, M., & Mačuks, R. (2016) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000259 · Cited by 13
Nie, D., Mao, X., & Li, Z. (2019) · Journal of Cancer · doi:10.7150/jca.29896 · Cited by 13
“Epithelial ovarian cancer (EOC) is a group of diseases with distinct clinical and histopathological features.[1, 2] Additionally, the incidence rate of lymph nodes (LNs) metastasis also differ in different EOC histological types and grades.”
BackgroundWang, C., Winterhoff, B. J. N., Kalli, K. R., Block, M. S., Armasu, S. M., Larson, M. C., Chen, H., Keeney, G. L., Hartmann, L. C., Shridhar, V., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.124 · Cited by 13
“With an estimated 21 290 new cases in 2015 (Siegel et al, 2015), epithelial ovarian cancer (EOC) is a heterogeneous disease from morphological and molecular perspectives (Kobel et al, 2008; Cancer Genome Atlas Research Network, 2011).”
BackgroundDicer and Drosha in Ovarian Cancer
Köbel, M., Gilks, C. B., & Huntsman, D. D. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090085 · Cited by 13
Self-citationPrognostic utility of the ovarian cancer secretome: a systematic investigation
Kamble, P. R., Breed, A. A., Pawar, A., Kasle, G., & Pathak, B. R. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06361-8 · Cited by 12
Saldanha, E., Desai, S. M., Patel, D. G., Dhakad, V., Joseph, B., Ghosh, S., Prakash, V., Deepti, H., & Monteiro, A. D. (2022) · South Asian Journal of Cancer · doi:10.1055/s-0042-1751098 · Cited by 12
Cabañas, C., Rossi, E., Bartolomé, R. A., Doberstein, K., Altevogt, P., Casal, J. I., & Bernabéu, C. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00787-7 · Cited by 12
Guadagno, E., Pignatiello, S., Borrelli, G., Cervasio, M., Corte, L. D., Bifulco, G., & Insabato, L. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152633 · Cited by 12
Song, Z., Wang, X., Fu, J., Wang, P., Chen, X., & Zhang, D. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2022.1068492 · Cited by 12
Hormone receptors and ovarian cancer survival
Gourley, C. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70323-1 · Cited by 12
Kim, M., Kim, M. A., Kim, H., Kim, Y.-B., & Song, Y. S. (2014) · BioMed Research International · doi:10.1155/2014/495754 · Cited by 12
“and compared between different subtypes of ovarian cancer which are now considered as different disease entities with distinct biomarker expression profiles [8, 9].”
BackgroundMissaoui, N., Salhi, S., Bdioui, A., Mestiri, S., Abdessayed, N., Mokni, M., & Yacoubi, M. T. (2018) · PubMed Central · doi:10.22034/apjcp.2018.19.9.2545 · Cited by 12
“…intra- and interobserver variability and poor reproducibility of the diagnosis (Abdelaal et al., 2016; Bian et al., 2014; Cymbaluk-Ploska et al., 2016; Gilks et al., 2008; Köbel et al., 2008; Köbel et al., 2010a; Köbel et al., 2010b; Köbel et al., 2016; Köbel et al., 2018; Seidman et al., 2015).”
BackgroundInfluentialGavrielides, M. A., Miller, M., Hagemann, I. S., Abdelal, H. A., Alipour, Z., Chen, J., Salari, B., Sun, L., Zhou, H., & Seidman, J. D. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0390-oa · Cited by 12
Magnetic Resonance Imaging Characteristics of Ovarian Clear Cell Carcinoma
Wang, W., Ding, J., Zhu, X., Li, Y., Gu, Y., & Peng, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132406 · Cited by 12
“Compared with other histological types, OCCC accounts for 5%-10% of all ovarian tumors[14] and has unique molecular characteristics as well as specific biological and clinical features[14, 15].”
BackgroundManagement of borderline ovarian tumours
Bagade, P., Edmondson, R. J., & Nayar, A. (2012) · The Obstetrician & Gynaecologist · doi:10.1111/j.1744-4667.2012.00102.x · Cited by 12
Bălescu, I., Eftimie, M. A., Petrea, S., Diaconu, C. C., Gașpar, B. S., Pop, L. B., Varlas, V. N., Hasegan, A. G., Martac, C., Bolca, C. N., et al. (2024) · Cancers · doi:10.3390/cancers16020254 · Cited by 11
“…in advanced stages of the disease [1]; moreover, there are also cases in which ovarian cancer cells do not induce the apparition of increased levels of this antigen due to their incapacity to secrete it; in such cases, normal ranges of CA125 are encountered for a long period of time [2,3].”
BackgroundGlobal characterization of RNA editing in genetic regulation of multiple ovarian cancer subtypes
Wang, Y., Wu, J., Zhao, J. G., Xu, T., Zhang, M., Liu, J., Wang, Y., Wang, Q., & Song, X. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102127 · Cited by 12
“7 These differences should be re fl ected in clinical study design and, ultimately, in the treatment of OV.”
BackgroundA Case of Obstructive Jaundice Caused by Metastasis of Ovarian Cancer to the Duodenal Major Papilla
Takasaki, Y., Irisawa, A., Shibukawa, G., Sato, A., Abe, Y., Yamabe, A., Arakawa, N., Maki, T., Yoshida, Y., Igarashi, R., et al. (2018) · Clinical Medicine Insights Case Reports · doi:10.1177/1179547618791571 · Cited by 11
Zhang, Y., Qiao, C., Li, L., Zhao, X., & Li, Y. (2015) · African Health Sciences · doi:10.4314/ahs.v14i4.20 · Cited by 11
Comparison of Pure and Mixed-Type Clear Cell Carcinoma of the Ovary
Ye, S., You, Y., Yang, J., Cao, D., Bai, H., Huang, H., Wu, M. P., Chen, J., Lang, J., & Shen, K. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000275 · Cited by 11
Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers
McGee, J., Kotsopoulos, J., Lubiński, J., Lynch, H. T., Rosen, B. P., Tung, N., Kim‐Sing, C., Karlan, B. Y., Foulkes, W. D., Ainsworth, P., et al. (2012) · Obesity · doi:10.1038/oby.2011.394 · Cited by 11
“Despite this, there is increasing evidence suggesting that combining histologic subtypes may in fact be obscuring possible significant associations due to differences in etiology (24,25).”
BackgroundHarnessing The Potential of Lipid-Based Nanomedicines for Type-Specific Ovarian Cancer Treatments
Leung, A. W. Y., Kalra, J., Santos, N. D., Bally, M. B., & Anglesio, M. S. (2014) · Nanomedicine · doi:10.2217/nnm.13.220 · Cited by 11
Anti-HE4 antibodies in infertile women and women with ovarian cancer
Hellström, I., Swisher, E. M., Hellström, K. E., Yip, Y. Y., Agnew, K. J., & Luborsky, J. L. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.028 · Cited by 11
“It is expressed in endometrioid ovarian tumors [36], the most common tumor type associated with endometriosis.”
Aslan, K., Meydanlı, M. M., Akıllı, H., Durmus, Y. E., Gökçü, M., Kayıkçıoğlu, F., Demirkıran, F., & Ayhan, A. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05580-9 · Cited by 11
Walsh, M. F., Cadoo, K. A., Salo‐Mullen, E. E., Dubard-Gault, M. E., Stadler, Z. K., & Offit, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00013-x · Cited by 11
Salnikova, L. E. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8290-1 · Cited by 11
“The use of raw p values in the studies with similar approach is discussed in detail, with prior biological knowledge as a first major turning point (Köbel et al. 2008; Leiserson et al. 2013).”
Nassir, M., Darb‐Esfahani, S., Richter, R., Chekerov, R., Hall, C. S., Muallem, M. Z., Denkert, C., Stamatian, F. V., Fotopoulou, C., Sehouli, J., et al. (2013) · PubMed · Cited by 11
Filippou, P. S., & Dey, P. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00088 · Cited by 10
Skírnisdóttir, I., Mayrhofer, M., Rydåker, M., Åkerud, H., & Isaksson, A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-407 · Cited by 10
“; licensee BioMed Ce Creative Commons Attribution License (http:/ distribution, and reproduction in any medium strongly associated with histological sub-type than with stage of the disease [2-5] and as a consequence of that they should be analyzed separately [2,6].”
BackgroundProteomics discovery of chemoresistant biomarkers for ovarian cancer therapy
Deng, J., Wang, L., Ni, J., Beretov, J., Wasinger, V. C., Wu, D., Duan, W., Graham, P., & Li, Y. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1233065 · Cited by 10
Kaltofen, T., Preinfalk, V., Schwertler, S., Fraungruber, P., Heidegger, H. H., Vilsmaier, T., Vattai, A., Czogalla, B., Mayr, D. C., Mahner, S., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03317-4 · Cited by 10
“Moreover, the cell line A2780 mainly represents features of the endometrioid subtype (Anglesio et al. 2013; Köbel et al. 2008) and is thus not able to act as a reliable model for all histological subtypes of EOC.”
BackgroundShafrir, A. L., Babić, A., Gates, M. A., Rice, M. S., Townsend, M. K., Hecht, J. L., & Tworoger, S. S. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0618 · Cited by 10
Gavrielides, M. A., Ronnett, B. M., VANG, R. S., Barak, S., Lee, E., Staats, P. N., Jenson, E., Skaria, P., Sheikhzadeh, F., Miller, M., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0579-oa · Cited by 10
Multi-view Unsupervised Feature Selection via Consensus Guided Low-rank Tensor Learning
Wang, L., Liang, C., Dong, W., & Chen, W. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9995699 · Cited by 9
Immunohistochemistry Markers in Ovarian and Fallopian Tube Neoplasms: a Comprehensive Review
Gupta, S., Ahuja, S., & Kalwaniya, D. S. (2024) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-024-02049-y · Cited by 9
“Studies suggest that molecular subgrouping correlates better with prognosis than traditional morphological evaluation as low-grade p53abn ENOCs exhibit aggressive behavior, whereas high-grade POLE ENOCs have a favorable prognosis [20].”
Autophagy in clear cell ovarian cancer, a potential marker for hypoxia and poor prognosis?#
Gibson, S. B. (2012) · The Journal of Pathology · doi:10.1002/path.4100 · Cited by 9
Patrick, E., Schramm, S., Ormerod, J. T., Scolyer, R. A., Mann, G. J., Mueller, S., & Yang, J. Y. H. (2016) · Oncotarget · doi:10.18632/oncotarget.13203 · Cited by 9
“That is, pre-determining potential confounding variables before an experiment without sufficient evidence and using these to subset a cohort might have unnecessarily reduced power or further confounded the analysis [1, 11, 12].”
BackgroundLalos, A., Neri, O., Ercan, C., Wilhelm, A., Staubli, S. M., Posabella, A., Weixler, B., Terracciano, L., Piscuoglio, S., Stadlmann, S., et al. (2021) · Cancers · doi:10.3390/cancers13225783 · Cited by 9
Wu, Y., You, Y., Chen, L., Liu, Y., Liu, Y., Lou, W., & Fu, F. (2022) · Gland Surgery · doi:10.21037/gs-22-29 · Cited by 9
Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma
Jiabo, D., Refika, Y., Carl, G., Tjitske, D.-D. B., Leon, M., & Torensma, R. (2010) · Journal of Cancer Therapy · doi:10.4236/jct.2010.14026 · Cited by 9
“Taken together, our study revealed that ovarian cancer is a heterogonous disease [33] and all the reported putative ovarian CSC markers are not applicable to isolate CSCs from all patients.”
Backgroundvon Heideman, A., Tholander, B., Grundmark, B., Cajander, S. B., Gerdin, E., Holm, L., Axelsson, A., Rosenberg, P., Mahteme, H., Daniel, E., et al. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.794956 · Cited by 9
Evidence for the Relationship Between Endometriosis and Epithelial Ovarian Cancer
Carmen, M. G. D. (2015) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000218 · Cited by 9
The functional consequences and prognostic value of dosage sensitivity in ovarian cancer
Yan, Z., Liu, Y., Wei, Y., Zhao, N., Zhang, Q., Wu, C., Chang, Z., & Xu, Y. (2016) · Molecular BioSystems · doi:10.1039/c6mb00625f · Cited by 9
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Andersson, Y., Haavardtun, S. I., Davidson, B., Dørum, A., Fleten, K. G., Fodstad, Ø., & Flatmark, K. (2017) · Oncotarget · doi:10.18632/oncotarget.18694 · Cited by 9
“Tumor tissues were analyzed with respect to expression of a range of proteins with relevance for characterizing EOC subtypes and to discriminate between EOC and malignant mesothelioma [9, 16].”
BackgroundIL‑6 prevents CXCL8‑induced stimulation of EpCAM expression in ovarian cancer cells
Kapka‐Skrzypczak, L., Popek-Marciniec, S., Sawicki, K., Drop, B., Czajka, M., Jodłowska‐Jędrych, B., Matysiak‐Kucharek, M., Furman‐Toczek, D., Zagórska-Dziok, M., & Kruszewski, M. K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9890 · Cited by 9
“In human epithelial ovarian cancer, EpCAM is overexpressed consistently across all histological subtypes (3,4).”
BackgroundLi, H., Tang, W., Feng, F., Zhao, S. H., Gu, W. Y., Zhang, G., & Qiang, J. (2020) · Acta Radiologica · doi:10.1177/0284185119898654 · Cited by 9
“Recurrence of tumor is an important risk factor for death in patients with EOC (4).”
BackgroundResultBMI-1 Expression Heterogeneity in Endometriosis-Related and Non-Endometriotic Ovarian Carcinoma
Lozneanu, L., Balan, R. A., Păvăleanu, I., Giuşcă, S. E., Căruntu, I.-D., & Amălinei, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116082 · Cited by 9
“Many studies have shown that the CA125 profiles of HGSC and HGEC are different from other subtypes [50].”
BackgroundSearching for a system: The quest for ovarian cancer biomarkers
Rodland, K., & Maihle, N. J. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0216 · Cited by 9
“…of diagnostics: highly sensitive markers of disease that are of necessity less specific for the site of origin, followed by more speci fi c (but less sensitive) markers that point to the source of the disruption [39], and that would further differentiate be-tween benign and malignant processes.”
InfluentialAmankwah, E. K., Wang, Q., Schildkraut, J. M., Tsai, Y.-Y., Ramus, S. J., Fridley, B. L., Beesley, J., Johnatty, S. E., Webb, P. M., Chenevix‐Trench, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019642 · Cited by 9
“By restricting the samples to serous epithelial ovarian cancers, we reduced etiologic heterogeneity that may exist among different histological types of ovarian cancer [38].”
BackgroundNameki, R. A., Chang, H. S. Y., Yu, P. H., Abbasi, F., Lin, X., Reddy, J., Haro, M., Fonseca, M. A., Freedman, M. L., Drapkin, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.11.536378 · Cited by 9
“…positivity rate; standard deviation, 0.27), and 86% of fallopian tube tissues (0.19 mean positivity rate; standard deviation, 0.13) expressed WT1, but this marker was less commonly expressed in non-high-grade serous subtypes (Acs et al., 2004; Köbel et al., 2008; Shimizu et al., 2000) (Table 1) .”
InfluentialScebba, F., Salvadori, S., Cateni, S., Mantellini, P., Carozzi, F., Bisanzi, S., Sani, C., Robotti, M., Barravecchia, I., Martella, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115716 · Cited by 8
“OC is a heterogeneous disease comprising several types and subtypes [3,4], and the extra-ovarian origins of epithelial OC contribute to its intricacies.”
BackgroundMolecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma
Da-Anoy, A., Kang, E. Y., Lee, C., Cheasley, D. A., Llauradó, M., Carey, M. S., Cameron, A., & Köbel, M. (2024) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000001043 · Cited by 8
“With the recognition that ovarian carcinoma histotypes are different diseases 31 , the treat-ment of LGSC has undergone dramatic changes with alternative options to adjuvant chemotherapy.”
Self-citationOVision A raspberry Pi powered portable low cost medical device framework for cancer diagnosis
Mehta, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-91914-z · Cited by 8
Acland, M., Arentz, G., Mussared, M., Whitehead, F., Hoffmann, P., Klingler‐Hoffmann, M., & Oehler, M. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.523989 · Cited by 8
Duarte, J. D. G., Quigley, L. T., Young, A. R., Hayashi, M., Miyazawa, M., Lopata, A., Mancuso, N., Mikami, M., Behren, A., & Meeusen, E. N. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011220 · Cited by 8
BRAF mutational analysis in ovarian tumors: recent perspectives
Wong, K., Gershenson, D. M., & Tsai, C.-C. (2015) · Pathology and Laboratory Medicine International · doi:10.2147/plmi.s64383 · Cited by 8
“41 No germline mutation of BRAF has been found, and thus the presence of BRAF mutation is probably not a genetic pre-disposition for the development of SBTs. 16 Although a high percentage of stage II–IV SBTs with noninvasive implants have progressed to invasive LGSCs when patients were observed for…”
The Role of the Immune System in Ovarian Cancer and Implications on Therapy
Menderes, G., Schwab, C. L., Black, J., & Santin, A. D. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1147957 · Cited by 8
“studied biomarkers in four OC subtypes (high-grade serous, clear-cell, endometrioid, and mucinous tumors) and EpCAM demonstrated consistent high expression across subtypes [44].”
BackgroundHanley, G. E., Rozenberg, N., & McAlpine, J. N. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000315 · Cited by 8
“All gynecologic surgeons were asked to consider: (1) performing bilateral salpingectomy in all women at the time of hysterectomy (even when ovaries are being preserved); (2) performing bilateral salpingectomy in place of tubal ligation for sterilization; and (3) referring all HGSCs to the hereditary cancer program for…”
BackgroundImmunophenotypic profile as a predictor of prognosis in advanced ovarian carcinoma
Yokoi, A., Matsumoto, T., Watanabe, G., Tochimoto, M., & Saegusa, M. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.10.036 · Cited by 8
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
Kasimir‐Bauer, S., Roder, J., Obermayr, E., Mahner, S., Vergote, I. B., Loverix, L., Braicu, E. I., Sehouli, J., Concin, N., Kimmig, R., et al. (2020) · Cancers · doi:10.3390/cancers12092519 · Cited by 8
“The potential of proteomics-guided therapy stratification in EOC was highlighted over a decade ago [5,6].”
BackgroundZhu, Y., He, L.-S., Zhang, Z., & Huang, Q. H. (2012) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(12)60175-8 · Cited by 8
“theories of “dualistic pathology model”[2,3] and “heterogeneity of ovarian carcinomas”[4,5] for pathogenic mechanism of ovarian carcinomas.”
Background
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.